Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From dosing protocols in Phase II trials to patent claims on deuterated psilocybin, Cybin’s SEC paperwork demands deep scientific and regulatory fluency. If you have ever scrolled through a 300-page prospectus searching for trial endpoints or waited for an 8-K that confirms a breakthrough-therapy meeting, you know the pain. Stock Titan solves it: our AI instantly converts dense disclosures into plain-English briefs, surfaces red-flag risks, and links each note back to the original page so you can verify facts in seconds. In short, consider this “Cybin SEC filings explained simply.”
Whether you need the full “Cybin annual report 10-K simplified” or want “Cybin quarterly earnings report 10-Q filing” highlights, we cover every form the moment it hits EDGAR. Real-time alerts track “Cybin Form 4 insider transactions real-time,” while interactive dashboards group every “Cybin insider trading Form 4 transactions” by executive and clinical milestone. Our engine delivers “Cybin 8-K material events explained,” maps R&D spend, and even decodes the “Cybin proxy statement executive compensation” tables so you see option grants in context. The AI-powered summaries update with each amendment, ensuring you are always reading the most current version.
Use the data the way professionals do: compare quarter-over-quarter trial costs, monitor “Cybin executive stock transactions Form 4” before key readouts, and share “Cybin earnings report filing analysis” with colleagues in one click. Still “understanding Cybin SEC documents with AI”? Our platform overlays definitions, creates custom peer benchmarks, and archives every footnote for audit trails. From first clinical IND to commercial launch, Stock Titan equips you with comprehensive coverage, expert commentary, and the clarity needed to make informed decisions faster than the market.
Cybin Inc. (CYBN) filed a new Form D for an exempt offering under Rule 506(b). The notice covers stock options exercisable at CAD$8.39 per share, vesting in eight quarterly tranches beginning December 31, 2025.
Total amount sold is $0 USD, with $601,865 USD remaining to be sold. The company notes the total represents the maximum potential proceeds from option exercises. The filing lists a Date of First Sale: October 1, 2025, and reports $0 in finders’ fees. The issuer is incorporated in Ontario, Canada and identifies its industry as health care/biotechnology.
CYBIN INC. filed a Form D for a new, Regulation D exempt offering under Rule 506(b) to register up to $120,070 USD in potential proceeds, which represents the maximum amount potentially received from the exercise of stock options. No proceeds have been sold yet and total remaining to be sold is $120,070 USD. The securities consist primarily of stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The offering is intended to last more than one year. No sales commissions or finders’ fees were disclosed and no proceeds are allocated to named executives or directors. One investor is reported and one non-accredited investor has participated.
CYBIN Inc. discloses a shelf prospectus supplement highlighting clinical-stage psychedelic drug development and material risks. The filing emphasizes that psilocin is not approved by Health Canada or the U.S. FDA and that the company does not handle controlled substances except within licensed laboratory or clinical trial settings. The company warns of substantial quarter-to-quarter losses and uncertainty about its ability to raise additional funding. Key development milestones include topline efficacy readout from the first Phase 3 study (APPROACH) for deuterated psilocin (CYB003), progression of two additional Phase 3 studies (EMBRACE, EXTEND), a Phase 2 GAD topline readout for deuterated DMT (CYB004), and advancing a drug development candidate from the phenethylamine/tryptamine program (CYB005). The filing notes reliance on third parties for trials and manufacturing and risk from changing laws across multiple jurisdictions.
CYBIN Inc. discloses financing and operational risks and outlines clinical development milestones across three programs. The company warns of uncertainty in raising additional funds, potential continued substantial losses, pandemic-related risks, regulatory constraints around psychedelic substances, and reliance on key personnel. It states it does not currently handle controlled substances outside approved laboratory or clinical settings and would need licenses and approvals to do so directly.
The filing lists near-term development objectives: topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for deuterated psilocin (CYB003); completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004); delivery of a drug development candidate for the phenethylamine and tryptamine derivatives program (CYB005); and use of proceeds for working capital and general corporate purposes.
CYBIN Inc. is offering securities via a secondary prospectus supplement and outlines risks, regulatory constraints and clinical-development milestones. The document emphasizes that the company currently does not handle controlled or restricted substances under Canadian or U.S. law and only works with psychedelic compounds within approved laboratory and clinical-trial frameworks or via third parties where required. Key near-term development objectives include topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for the deuterated psilocin program (CYB003), completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004), and delivery of a drug development candidate for the phenethylamine/tryptamine derivatives program (CYB005). The prospectus warns of continuing substantial losses, pandemic risks, potential clinical-trial delays, reliance on key personnel, and regulatory changes across multiple jurisdictions.
CYBIN Inc. discloses risks around a proposed secondary offering, including uncertainty in raising additional funding and continued substantial losses. The company emphasizes regulatory constraints on psychedelic substances in key jurisdictions and states it currently does not handle controlled substances outside approved laboratory or clinical trial settings. Clinical development milestones are outlined: Phase 3 topline readout for deuterated psilocin (CYB003) and progression of two additional Phase 3 studies, a Phase 2 completion and topline readout for deuterated DMT (CYB004), and delivery of a drug development candidate from the CYB005 program. Proceeds are intended for working capital and general corporate purposes.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
